Phase 2 Colorectal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent to take part in the study
• People aged between 18 and 75 years old, of any gender
• People who have been diagnosed with a specific type of rectal cancer (called pMMR/MSS rectal adenocarcinoma) confirmed by tissue testing
• People whose tumor is located within 10 cm of the opening of the back passage
• People whose cancer has been assessed by imaging as being at a certain stage — specifically, a tumor that has grown beyond the rectal wall (called T3 or T4) with certain high-risk features visible on scans, and no distant spread
• People whose cancer is expected to be fully removable by surgery (called R0 resection)
• People who are able to swallow tablets
• People who are in good general health, rated 0 or 1 on a standard activity scale used by doctors (ECOG scale)
• People who have not had any prior treatment for their rectal cancer
• People who are planning to have surgery after completing the pre-surgery treatment in this trial
• People who have no medical reasons preventing them from having surgery
• People whose blood, liver, kidney, and clotting function results fall within acceptable ranges on tests taken before starting the trial
• Women who could become pregnant must have a negative pregnancy blood test within 72 hours before starting treatment, and must use effective contraception during the trial and for at least 3 months after the last dose; male participants whose partner could become pregnant must also use effective contraception during the trial and for 3 months after the last dose

Who may not be able to join:

• People with a known allergy to monoclonal antibodies or to any of the study drugs (camrelizumab, fluzoparib, capecitabine, oxaliplatin, or other platinum-based drugs)
• People who have previously received, or are currently receiving, radiotherapy, chemotherapy, or any other cancer treatment for rectal cancer; have taken immunosuppressive or high-dose steroid medications within 2 weeks before the trial; received a live vaccine within 4 weeks before the trial; or had major surgery or serious injury within 4 weeks before the trial
• People with an active autoimmune disease or a significant history of autoimmune conditions (such as lung inflammation, bowel inflammation, hepatitis, or others) — some conditions that are fully resolved may be considered (confirm with trial site)
• People with a weakened immune system, a positive HIV test, other immune deficiency conditions, or a history of organ or bone marrow transplant
• People with serious or poorly controlled heart conditions, including significant heart failure, unstable chest pain, a heart attack within the past year, or uncontrolled abnormal heart rhythms
• People who have had a serious infection within 4 weeks before the trial, such as severe pneumonia or a bloodstream infection requiring hospital treatment
• People with active tuberculosis, or a history of tuberculosis within the past year, or a history of tuberculosis more than a year ago that was not properly treated
• People with active hepatitis B or hepatitis C infections above certain measurable levels
• People who have been diagnosed with another cancer within the past 5 years — although some low-risk skin cancers or fully treated cervical pre-cancers may be considered (confirm with trial site)
• Women who are pregnant or breastfeeding
• People who, in the treating doctor's judgement, have other serious conditions (including psychiatric illness), alcohol or drug misuse, or personal circumstances that could make participation unsafe or difficult

Important: Always verify eligibility with the trial site directly before applying.